- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Azidothymidine, NSC 602670 中文名稱:齊多夫定,疊氮胸苷
Zidovudine (ZDV, Azidothymidine, NSC 602670)是一種逆轉(zhuǎn)錄酶抑制劑。它能夠降低同源重組效率。Zidovudine降低了CRISPR介導的特定序列基因組敲入效率,但增強了其敲除效率。
Zidovudine Chemical Structure
CAS: 30516-87-1
相關(guān)靶點 | HBV RT HIV RT RT | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | Dapivirine (TMC120) Salicylanilide Fangchinoline | 點擊展開 |
相關(guān)化合物庫 | 抗感染化合物庫 抗生素化合物庫 抗病毒化合物庫 抗寄生蟲藥物庫 腸道微生物代謝物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
PBMC | Function assay | 1 μM | Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM, IC50=0.00014 μM | 16420027 | |
human H9 cells | Function assay | 6 days | Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA, IC50=0.3 nM | 20086149 | |
MT4 cells | Function assay | 4 days | Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay, EC50=0.7 nM | 17964796 | |
human MT2 cells | Function assay | 1 h | Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA, EC50=1.2 nM | 18316521 | |
human H9 cells | Cytotoxicity assay | 6 days | Cytotoxicity against human H9 cells after 6 days by MTT assay, EC50=0.01 μM | 20846868 | |
human C8166 cells | Function assay | Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect, EC50=4e-06 μM | 21534540 | ||
AA5 cells | Function assay | Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay, IC50=0.3 nM | 20086149 | ||
CEM cells | Function assay | Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells, EC50=0.32 nM | 2153206 | ||
C8166 cells | Function assay | Inhibition of HIV1-3B replication in C8166 cells, EC50=1.9 nM | 16279773 | ||
CEM-SS cell | Function assay | Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line, IC50=0.002 μM | 7650678 | ||
PBLs | Function assay | Antiviral activity against subtype isolate G strain in PBLs (peripheral blood lymphocytes), IC50=0.002 μM | 11708913 | ||
human lymphocyte CEM/0 cell line | Function assay | Anti HIV-1 activity in human lymphocyte CEM/0 cell line, EC50=0.003 μM | 8478904 | ||
Jurkat cell | Function assay | Inhibitory concentration against HIV-1 infected Jurkat cell lines, IC50=0.01 μM | 7837220 | ||
C3H/3T3 cells | Function assay | Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%, EC50=0.02 μM | 2016718 | ||
U937 cells | Function assay | Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay, EC50=0.03 μM | 7932526 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Zidovudine (ZDV, Azidothymidine, NSC 602670)是一種逆轉(zhuǎn)錄酶抑制劑。它能夠降低同源重組效率。Zidovudine降低了CRISPR介導的特定序列基因組敲入效率,但增強了其敲除效率。 | |
---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | 在新近感染的T和單核細胞,但不是在慢性感染的細胞中,Zidovudine預處理具有有效的抗HIV-1活性。[1] Zidovudine抑制的逆轉(zhuǎn)錄適度降低p24抗原水平,降低HIV-1的gag19倍,并抑制檢測的2-LTR的HIV-1的DNA。[2] 在培養(yǎng)的Kearns-Sayre綜合征成纖維細胞中,Zidovudine和脫氧核苷耗盡野生型線粒體DNA水平,并增加刪除線粒體DNA水平。[3] Zidovudine(AZT,0.1-50 mM)對粒細胞-單核細胞集落形成單位(CFU-GM)的集落的生長有濃度依賴性抑制作用。Zidovudine也引起對GM-CSF受體型α(GM-CSF受體阿爾法)基因表達的濃度依賴性抑制效果(35-90%)。Zidovudine導致低得多的IL-3受體型α(IL-3R α)消息的水平的減少(15-22%),對甘油醛-3-磷酸脫氫酶(GAPDH)和c-myc消息級別沒有顯著的效果。[4] Zidovudine導致濃度依賴性抑制生成素受體和c-fos的mRNA水平,而對c-myc基因的mRNA水平不受影響。Zidovudine也濃度和時間依賴的方式抑制蛋白激酶C(PKC)活性,在10 mM3小時以內(nèi)引起50%抑制。Zidovudine誘導Epo受體和c-fos表達的下調(diào),伴隨著Epo受體介導的信號轉(zhuǎn)導的抑制,對AZT誘導紅細胞毒性有顯著促成因素。[5] Zidovudine可降低HDR的效率。它降低了CRISPR介導的特定序列基因組敲入效率,而增強了其敲除效率[6]。 |
---|
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT03991013 | Completed | HIV Infections |
University of Cape Town|Wellcome Trust|Médecins Sans Frontières Belgium |
August 8 2019 | Phase 2 |
NCT03642704 | Completed | Mother to Child HIV Transmission |
ANRS Emerging Infectious Diseases |
February 22 2017 | Phase 4 |
分子量 | 267.24 | 分子式 | C10H13N5O4 |
CAS號 | 30516-87-1 | SDF | Download Zidovudine SDF |
Smiles | CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-] | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 53 mg/mL ( (198.32 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Ethanol : 53 mg/mL (198.32 mM) Water : 26 mg/mL (97.29 mM) |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
Do you happen to have any information regarding the half-life of AZT?
回答:
The Half-life of S2579 in human is available (http://www.rxlist.com/retrovir-drug/clinical-pharmacology.htm), about 0.5-3 hours in adult subjects.